Deep Vein Thrombosis Market Size, Share & Trends Analysis Report By Treatment (Clot Busters, Blood Thinners, Inferior Vena Cava Filters, Compression Stockings, Others), By Distribution Channel, Region And Segment Forecasts, 2023-2031.

Report Id: 1070 Pages: 180 Published: 06 February 2025 Format: PDF / PPT / Excel / Power BI
Share With : linkedin twitter facebook

The Deep Vein Thrombosis Market Size is valued at 958.11 Million in 2022 and is predicted to reach 1343.86 Million by the year 2031 at a 4.0 % CAGR during the forecast period for 2023-2031.

Deep Vein Thrombosis Market

Deep vein thrombosis (DVT) is a serious condition that occurs when clots forms in the deep veins of the body. The most dangerous complication of deep vein thrombosis is pulmonary embolism (PE), which can either be asymptomatic or symptomatic. Surgery and pregnancy are the major risk factors associated with deep vein thrombosis. Pregnancy increase hormone level and slower blood flow lead to expansion of uterus and restrict blood flowing back from lower extremities responsible for deep vein thrombosis. Diagnosis of deep vein thrombosis can be made with blood tests such as D-dimer test and imaging tests such as Doppler ultrasound (Duplex), contrast venogram, magnetic resonance imaging (MRI), and computer tomography (CT). There are four types of treatments for deep vein thrombosis include anticoagulant, thrombolytic therapy, IVC filters (Vein Filters), and Stents. Anticoagulant such as unfractionated heparin, low molecular weight heparin (enoxaparin/ Lovenox, dalteparin/Fragmin, or tinzaparin/Innohep, fondaparinux/Arixtra or desirudin/Iprivask), warfarin (Coumadin and Jantoven) are the primary treatment deep vein thrombosis. Thrombolytic therapy such as tissue plasminogen activator agents (tPA) can help to dissolve the blood clot. IVC filters (Vein Filters), also known as “Greenfield filters,” is an umbrella-shaped device that is placed into the large vein, which traps blood clots and prevents deep vein thrombosis and pulmonary embolism. Stents are metal meshwork tubes that are placed into a vein to keep them open.

Market Segmentation

Deep Vein Thrombosis market is segmented into Treatement, Distribution channel and Region. On the basis of Treatment, market is segmented into Clot Busters, Blood Thinners, Inferior Vena Cava Filters, Compression Stockings, Others, on the other side, By Distribution Channel, market is devided into Retail Pharmacy, Hospital Pharmacy, and E-commerce. Regionally, market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Almost one-half million patients are hospitalized for venous thromboembolism (consist of deep vein thrombosis and pulmonary embolism) each year in the United States. In Europe, there are 544,000 venous thromboembolism related death every year. Venous thromboembolism can cause a significant global economic burden. Various diagnostic tests and treatment, prolonged hospital stay, and follow-up care can be extremely costly; for instance estimated medical cost for venous thromboembolism in the U.S is $5-10 billion per year. In U.K venous thromboembolism related cost is 750 million per year. In Australia, venous thromboembolism related costs are estimated at 1.72 billion a year. In June 2017, U.S. FDA (Food and Drug Administration) approved betrixaban (Portola) for the adult with venous thromboembolism (VTE). Pentasaccharides such XARELTO are novel anticoagulants may be preferred over standard therapy due to few drug interactions and no need for frequent monitoring or re-dosing.

Competitive Landscape

Some of The Key Players in The Deep Vein Thrombosis Market:

  • Sandoz Inc.
  • Teva Pharmaceuticals USA, Inc.
  • Sanofi-Aventis U.S. LLC,
  • Baxter International Inc.,
  • West-Ward Pharmaceuticals,
  • Boehringer Ingelheim Pharmaceuticals, Inc.
  • Abbott Laboratories,
  • Bristol-Myers Squibb Company,
  • Pfizer,
  • Daiichi Sankyo Co. Ltd.,
  • Medtronic plc,
  • Johnson & Johnson,

The Deep Vein Thrombosis Market Report Scope

Report Attribute Specifications
Market Size Value In 2022 USD 958.11 Million
Revenue Forecast In 2031 USD 1343.86 Million
Growth Rate CAGR CAGR of 4.0 % from 2023 to 2031
Quantitative Units Representation of revenue in US$ Million and CAGR from 2023 to 2031
Historic Year 2019 to 2022
Forecast Year 2023-2031
Report Coverage The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends
Segments Covered By Treatment, By Distribution Channel
Regional Scope North America; Europe; Asia Pacific; Latin America; Middle East & Africa
Country Scope U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico; The UK; France; Italy; Spain; China; Japan; India; South Korea; South East Asia; South Korea; South East Asia
Competitive Landscape Sandoz Inc. Teva Pharmaceuticals USA, Inc. Sanofi-Aventis U.S. LLC, Baxter International Inc., West-Ward Pharmaceuticals, Boehringer Ingelheim Pharmaceuticals, Inc. Abbott Laboratories, Bristol-Myers Squibb Company, Pfizer, Daiichi Sankyo Co. Ltd., Medtronic plc, Johnson & Johnson, and others.
Customization Scope Free customization report with the procurement of the report, Modifications to the regional and segment scope. Particular Geographic competitive landscape.
Pricing and Available Payment Methods Explore pricing alternatives that are customized to your particular study requirements.

Segmentation of Deep Vein Thrombosis Market

Global Deep Vein Thrombosis Market Outlook By Treatment

  • Clot Busters
  • Blood Thinners
  • Inferior Vena Cava Filters
  • Compression Stockings
  • Others

Deep Vein Thrombosis Market

Global Deep Vein Thrombosis Market Outlook By Distribution Channel

  • Retail Pharmacy
  • Hospital Pharmacy
  • E-commerce

Global Deep Vein Thrombosis Market Outlook By Region

  • Europe
    • U.K.
    • Germany
    • France
    • Italy
    • Spain
    • Russia
    • Rest of Europe
  • North America
    • U.S.
    • Canada
  • Asia Pacific
    • India
    • China
    • Japan
    • South Korea
    • Australia & New Zealand
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa
    • GCC Countries
    • South Africa
    • Rest of Middle East & Africa

Need specific information/chapter from the report of the custom data table, graph or complete report? Tell us more.

Chapter 1. Methodology and Scope

1.1. Research Methodology

1.2. Research Scope & Assumptions

Chapter 2. Executive Summary

Chapter 3. Global Deep Vein Thrombosis Market Snapshot

Chapter 4. Global Deep Vein Thrombosis Market Variables, Trends & Scope

4.1. Market Segmentation & Scope

4.2. Drivers

4.3. Challenges

4.4. Trends

4.5. Investment and Funding Analysis

4.6. Industry Analysis – Porter’s Five Forces Analysis

4.7. Competitive Landscape & Market Share Analysis

4.8. Impact of Covid-19 Analysis

4.9. Clinical Trial/Pipeline Analysis

Chapter 5. Market Segmentation 1: By Treatment Estimates & Trend Analysis

5.1. By Treatment & Market Share, 2019 & 2031

5.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2022 to 2031 for the following By Treatment:

5.2.1. Clot Busters

5.2.2. Blood Thinners

5.2.3. Inferior Vena Cava Filters

5.2.4. Compression Stockings

5.2.5. Others

Chapter 6. Market Segmentation 2: By Distribution Channel Estimates & Trend Analysis

6.1. By Distribution Channel & Market Share, 2019 & 2031

6.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2022 to 2031 for the following By Distribution Channel:

6.2.1. Hospital Pharmacy

6.2.2. Retail Pharmacy

6.2.3. Online Pharmacy

Chapter 7. Deep Vein Thrombosis Market Segmentation 3: Regional Estimates & Trend Analysis

7.1. North America

7.1.1. North America Deep Vein Thrombosis Market revenue (US$ Million) estimates and forecasts By Treatment, 2023 - 2031

7.1.2. North America Deep Vein Thrombosis Market revenue (US$ Million) estimates and forecasts By Distribution Channel, 2023 - 2031

7.1.3. North America Deep Vein Thrombosis Market revenue (US$ Million) estimates and forecasts by country, 2023 - 2031

7.2. Europe

7.2.1. Europe Deep Vein Thrombosis Market revenue (US$ Million) By Treatment, 2023 - 2031

7.2.2. Europe Deep Vein Thrombosis Market revenue (US$ Million) estimates and forecasts By Distribution Channel, 2023 - 2031

7.2.3. Europe Deep Vein Thrombosis Market revenue (US$ Million) by country, 2023 - 2031

7.3. Asia Pacific

7.3.1. Asia Pacific Deep Vein Thrombosis Market revenue (US$ Million) By Treatment, 2023 - 2031

7.3.2. Asia Pacific Deep Vein Thrombosis Market revenue (US$ Million) estimates and forecasts By Distribution Channel, 2023 - 2031

7.3.3. Asia Pacific Deep Vein Thrombosis Market revenue (US$ Million) by country, 2023 - 2031

7.4. Latin America

7.4.1. Latin America Deep Vein Thrombosis Market revenue (US$ Million) By Treatment, (US$ Million)

7.4.2. Latin America Deep Vein Thrombosis Market revenue (US$ Million) estimates and forecasts By Distribution Channel, 2023 - 2031

7.4.3. Latin America Deep Vein Thrombosis Market revenue (US$ Million) by country, (US$ Million) 2023 - 2031

7.5. Middle East & Africa

7.5.1. Middle East & Africa Deep Vein Thrombosis Market revenue (US$ Million) By Treatment, (US$ Million)

7.5.2. Middle East & Africa Deep Vein Thrombosis Market revenue (US$ Million) estimates and forecasts By Distribution Channel, 2023 - 2031

7.5.3. Middle East & Africa Deep Vein Thrombosis Market revenue (US$ Million) by country, (US$ Million) 2023 - 2031

Chapter 8. Competitive Landscape

8.1. Major Mergers and Acquisitions/Strategic Alliances

8.2. Company Profiles

8.2.1. Sandoz Inc.

8.2.2. Teva Pharmaceuticals USA, Inc.

8.2.3. Sanofi-Aventis U.S. LLC,

8.2.4. Baxter International Inc.,

8.2.5. West-Ward Pharmaceuticals,

8.2.6. Boehringer Ingelheim Pharmaceuticals, Inc.

8.2.7. Abbott Laboratories,

8.2.8. Bristol-Myers Squibb Company,

8.2.9. Pfizer,

8.2.10. Daiichi Sankyo Co. Ltd.,

8.2.11. Medtronic plc,

8.2.12. Johnson & Johnson,

8.2.13. others

Name field cannot be blank!
Email field cannot be blank!(Use email format)
Designation field cannot be blank!
Company field cannot be blank!
Contact No field cannot be blank!
Message field cannot be blank!
4880
Security Code field cannot be blank!

Frequently Asked Questions

The Deep Vein Thrombosis Market Size is valued at 958.11 Million in 2022 and is predicted to reach 1343.86 Million by the year 2031.

The Deep Vein Thrombosis Market Size is expected to grow at a 4.0% CAGR during the forecast period.

Sandoz Inc. Teva Pharmaceuticals USA, Inc. Sanofi-Aventis U.S. LLC, Baxter International Inc., West-Ward Pharmaceuticals, Boehringer Ingelheim Pharmac

Treatment and Distribution Channel are the key segments of the Deep Vein Thrombosis Market.

North American region is leading the Deep Vein Thrombosis Market.
Get Sample Report Enquiry Before Buying